Ahead of Linagliptin going off-patent, NPPA fixes retail price of its FDC with Metformin
New Delhi: With the popular antidiabetic drug Linagliptin soon expected to go off-patent, the apex drug price regulator, National Pharmaceutical Pricing Authority (NPPA), has moved swiftly to pass on the benefit to the consumers by fixing the price of its fixed-dose combinations (FDC) with Metformin marketed by various companies such as Natco Pharma, Emcure Pharmaceuticals, Eris Lifesciences and Micro Labs.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage hyperglycemia in patients with type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Following the recent meeting the apex price regulator, the retail price of the formulation has been fixed for three Fixed Dose Combinations (FDCs) of Linagliptin and Metformin tablets which include:
S. No. | Name of the For mulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Re tail Price (Rs.) |
4(xxix)a | Linaglip ti n + Me tform i n Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Met for mi n Hyd roc hlo r id e IP 500m g | 1 Ta ble t | M/ s Optimus Pharma Pvt. Ltd. / M/ s Natco Pharma Ltd. | 8.04 |
4(xxix)b | Linaglipt in + Metformin Hy dro chloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hy d rochlo ride IP 500mg | 1 Tablet | M/ s MSN Laboratories Private Limited / M/ s Emcure Pharmaceuticals Limite d | 14 .65 |
4( xxix)c | Linagliptin + Metformin Hydrochloride Tablet | Ea ch film coated tablet contains : Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Table t | M/s MSN La boratories Private Limited / M/ s Eris Lifesciences Limited | 14.65 |
4(xxix)d | Linagliptin + Met form in Hydrochloride Tablet | Each film coated tablet contain s: Linagliptin 2.5mg Metformin Hydrochlori de IP 500mg | 1 Tablet | M/ s Micro Labs Limited | 10.63 |
4(xxix)e | Linagliptin + Met for mi n Hydrochloride Ta blet | Each film coated tablet contain s: Linagliptin 2.5mg Met for mi n Hy drochloride IP 1000mg | 1 Table t | M/s Optimu s Pharma Pvt. Ltd. / M/s Natco Pharma Ltd. | 8.37 |
4(xxix)f | Linagli ptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Me tformin Hydrochlor ide IP 1000mg | 1 Tablet | M/ s MSN La borator ies Private Limited / M/ s Emcure Pharmaceutica ls Limited | 16.33 |
4(xxix)g | Linagliptin + Metformin Hydrochlori de Tablet | Each film coated tablet contains : Linagliptin 2.5mg Met formin Hydrochlor ide IP 1000mg | 1 Tablet | M/ s Micro labs Limited | 11.52 |
4(xxix)h | Linaglipt in + Metformin Hydrochlor ide Tablet | Each film coated tablet contain s: Linag lipt in 2.5mg Metformin Hydrochlori de IP 850mg | 1 Tablet | M/ s MSN Laboratories Private Limited / M/ s Emcure Pharmaceuticals Limited | 15.45 |
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.